Current partner codePEPTIDESDE
NCT04931355·Not applicable·INTERVENTIONAL

Acupuncture in the Freeze-all IVF Cycle

Status

Unknown

Phase

Not applicable

Enrollment

90

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

In the early stage, our team found that Acupuncture intervention in freeze-all IVF cycles can improve the clinical pregnancy rate. In order to further study the role of Acupuncture in improving the pregnancy outcome of IVF-ET in infertility. A randomized controlled clinical trial will be used in this study. 90 infertile patients are randomly divided into two groups. The control group will be treated with conventional modern medicine, and the treatment group will be treated with Acupuncture on the basis of conventional modern medicine. The intervention starts from the 5th day of the menstrual cycle and lasts to the day before IVF-ET. The number of oocytes, antral follicles, AMH, serum FSH, and clinical pregnancy rate will be observed to evaluate the effect of Acupuncture on the improvement of pregnancy outcome. In addition, all of the participants will be asked to complete the self-evaluation of the anxiety/depression scale on the 7th day of the menstrual cycle, before and after transplantation, to analyze the emotional changes of the subjects during the study. We observe the safety and health economic indicators of Acupuncture treatment, so as to improve the overall efficacy of TCM Combined Application in assisted reproductive technology in the future.

Full detailed description

The study will be conducted on patients with DOR attending our reproductive medicine center for proposed IVF-ET between June 2021and December 2022. The trial is designed as a randomized, controlled clinical trial with two groups established by 1:1 equal allocation, a treatment group with interventions using acupuncture to tonify the kidneys and regulate blood and a control group treated using conventional Western medicine. Random numbers will be prepared by an independent third-party statistician who prepared a list of random group codes for this study. Enrolled subjects will be given a subject number during the screening process and, upon formal enrolment, will be randomly assigned to either the test or control group with a corresponding random number. The acupoints used will be: Zhongwan (RN12) :The needle should be punctured for 1-1.2 inches and retained for 30 minutes. Qihai(RN6): The needle should be punctured for 1-1.2 inches and retained for 30 minutes. Guanyuan(RN4): The needle should be punctured for 0.8-1.2 inches and retained for 30 minutes. Zhongji(RN3): The needle should be punctured for 0.8-1.0 inches and retained for 30 minutes. Guilai(ST29): The needle should be punctured for 0.8-1.0 inches and retained for 30 minutes. Shenshu(BL23): The needle should be punctured for 0.8-1.0 inches and retained for 30 minutes. Ciliao(BL28): The needle should be punctured for 1-1.2 inches and retained for 30 minutes. Xuehai(SP10): The needle should be punctured for 1-1.5 inches and retained for 30 minutes. Zusanli(ST36): The needle should be punctured for 1-1.5 inches and retained for 30 minutes. Diji(SP8): The needle should be punctured for 1-1.2 inches and retained for 30 minutes. Sanyinjiao(SP6): The needle should be punctured for 1-1.2 inches and retained for 30 minutes. Taixi(KI6): The needle should be punctured for 0.8-1.2 inches and retained for 30 minutes. Baihui(DU20): The needle should be punctured for 0.5-1.0 inches and retained for 30 minutes. Yintang(EX-HN3): The needle should be punctured for 0.5-1.0 inches and retained for 30 minutes. The Acupuncture intervention will start on the 5th day of the menstruation cycle, which will be carried out 1 time per day,at least 5 times a week, lasts for 10-15days. All operations were performed by experienced acupuncturists. After ET, both the control group and the treatment group will be treated with conventionally with no TCM intervention. Serum human chorionic gonadotropin (hCG) will be measured, and an hCG\>30 IU will be considered to indicate biochemical pregnancy. Ultrasound monitoring will be performed 30 days after ET to calculate the clinical pregnancy rate.

Interventions

Treatment arms and agents.

OTHER

Acupuncture

The Acupuncture intervention(Zhongwan、Qihai、Guanyuan、Zhongji、Guilai、Shenshu、Ciliao、Xuehai、Sanyinjiao、Taixi.) will start on the 5th day of menstruation cycle, which will be carried out 1 time per day, at least 5 times a week, lasts for 10-15days. All operations were performed by experienced acupuncturists. After ET, both the control group and the treatment group will be treated with conventionally with no TCM intervention.

OTHER

Western medicine

Western medicine

Timeline

From registration to results.

  1. First posted

    Jun 18, 2021

  2. Study start

    Jun 1, 2023

  3. Primary completion

    Dec 30, 2024

  4. Study completion

    Dec 30, 2024

  5. Results posted

    Not reported

  6. Registry updated

    May 31, 2023

Outcomes

What the study measures.

Primary outcomes

Clinical pregnancy rate (%)

Time frame · up to 6 weeks from enrollment

Follow up by telephone calls 14days after the IVF-ET

Secondary outcomes

Concentration of β-human Choriogonadotropin(β-HCG)

Time frame · up to 6 weeks from enrollment

Obtained by blood sampling 14 days after the proposed IVF-ET

Eligibility

Who can take part.

Minimum age
20 Years
Maximum age
40 Years
Sex
FEMALE
Healthy volunteers
No

Inclusion Criteria: 1. Meet the diagnostic criteria for infertility. 2. Meet the criteria for identifying kidney deficiency in TCM. 3. Patients who Planning to undergo IVF-ET for pregnancy in our center, Age ≤40 years and ≥25 years. 4. Previous embryo transfer failure ≥ 2 times. 5. Menstrual cycle is basically normal, and normal ovulation has been monitored in the past. 6. There were more than 1 blastocyst /more than 2 high-quality embryos with more than 6 cells on day 3/more than 2 high-quality embryos with more than 4 cells on day 2. 7. Consent to participate in this clinical trial and sign an informed consent form. Exclusion Criteria: 1. Patients with endometritis, acute pelvic inflammatory disease, mycotic vaginitis, bacterial vaginitis, adnexitis or other systemic infections. 2. It has been confirmed that there are obvious and serious other organic lesions in the reproductive organs. 3. Patients with allergic constitution 4. Infertility caused by genetic factors 5. Patients with serious primary diseases such as cardio cerebrovascular, kidney, liver and hematopoietic system and psychosis 6. A person who is unable to cooperate (such as a combination of neurological or mental illness, or a reluctance to cooperate) 7. The endometrial thickness on the day of hCG was less than 6 mm or the endometrial morphology on the day of hCG was type C 8. Those who did not agree to participate in the study

Study locations

1 registered sites.

China. Showing up to 24 locations stored in the fast local snapshot.

Peking University Third Hospital

Beijing, China, China

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Cetrorelix.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.